JP2023543898A5 - - Google Patents

Info

Publication number
JP2023543898A5
JP2023543898A5 JP2023520059A JP2023520059A JP2023543898A5 JP 2023543898 A5 JP2023543898 A5 JP 2023543898A5 JP 2023520059 A JP2023520059 A JP 2023520059A JP 2023520059 A JP2023520059 A JP 2023520059A JP 2023543898 A5 JP2023543898 A5 JP 2023543898A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutical composition
shtg
fpl
fcs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023520059A
Other languages
English (en)
Japanese (ja)
Other versions
JP7891470B2 (ja
JP2023543898A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/052001 external-priority patent/WO2022072244A1/en
Publication of JP2023543898A publication Critical patent/JP2023543898A/ja
Publication of JP2023543898A5 publication Critical patent/JP2023543898A5/ja
Application granted granted Critical
Publication of JP7891470B2 publication Critical patent/JP7891470B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023520059A 2020-10-02 2021-09-24 Apociii発現を減少させるための方法 Active JP7891470B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063087095P 2020-10-02 2020-10-02
US63/087,095 2020-10-02
PCT/US2021/052001 WO2022072244A1 (en) 2020-10-02 2021-09-24 Methods for reducing apociii expression

Publications (3)

Publication Number Publication Date
JP2023543898A JP2023543898A (ja) 2023-10-18
JP2023543898A5 true JP2023543898A5 (cg-RX-API-DMAC7.html) 2024-10-02
JP7891470B2 JP7891470B2 (ja) 2026-07-16

Family

ID=80950871

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023520059A Active JP7891470B2 (ja) 2020-10-02 2021-09-24 Apociii発現を減少させるための方法

Country Status (10)

Country Link
US (1) US20240033280A1 (cg-RX-API-DMAC7.html)
EP (1) EP4221720A4 (cg-RX-API-DMAC7.html)
JP (1) JP7891470B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230079394A (cg-RX-API-DMAC7.html)
CN (1) CN116348125A (cg-RX-API-DMAC7.html)
AU (1) AU2021353849A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023004012A2 (cg-RX-API-DMAC7.html)
IL (1) IL300882A (cg-RX-API-DMAC7.html)
MX (1) MX2023003855A (cg-RX-API-DMAC7.html)
WO (1) WO2022072244A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021521140A (ja) 2018-04-12 2021-08-26 ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. オリゴヌクレオチド組成物及びその使用方法
CA3098624A1 (en) 2018-05-11 2019-11-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
AU2023372971A1 (en) * 2022-11-02 2025-05-15 Ionis Pharmaceuticals, Inc. Methods for modulating complement factor b expression
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598227B2 (en) * 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
KR20200123263A (ko) * 2013-02-14 2020-10-28 아이오니스 파마수티컬즈, 인코포레이티드 지질단백질 리파제 결핍 (lpld) 모집단에서 아포지질단백질 c-iii (apociii) 발현의 조절
AU2016222548A1 (en) * 2015-02-27 2017-07-27 Ionis Pharmaceuticals, Inc. Modulation of apolipoprotein C-III (ApoCIII) expression in lipodystrophy populations
LT4119569T (lt) * 2015-11-06 2024-09-25 Ionis Pharmaceuticals, Inc. Konjuguoti priešprasmiai junginiai, skirti panaudoti terapijoje

Similar Documents

Publication Publication Date Title
RU2501803C2 (ru) Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 4 (fgfr4)
US10376533B2 (en) Compositions and methods for treating viral infections
JP2688113B2 (ja) 多発性硬化症の治療のための置換アデニン誘導体を含む薬学的組成物
JP2019511491A5 (cg-RX-API-DMAC7.html)
JP2017532982A (ja) Smad7アンチセンスオリゴヌクレオチドの同位体置換体
JP2026041749A5 (cg-RX-API-DMAC7.html)
JP2024037841A5 (cg-RX-API-DMAC7.html)
JP2018126141A5 (cg-RX-API-DMAC7.html)
BR112020018209A2 (pt) Composições farmacêuticas, recipiente pressurizado, e, métodos para tratar ou prevenir uma infecção viral e para tratar ou prevenir um coronavírus humano, coronavírus sars, coronavírus mers, vírus da encefalite equina oriental, vírus da encefalite equina ocidental, vírus da encefalite equina venezuelana, vírus da chicungunha, vírus ross river, rsv, vírus influenza a, vírus influenza b, vírus tacaribe, vírus pichinde, vírus junin, vírus da febre lassa, vírus da cariomeningite linfocitária, vírus da febre rift valley, vírus punta toro, vírus lacrosse, vírus maporal, vírus heartland, e vírus da síndrome de trombocitopenia de febre severa, poliovírus, vírus de coxsackie, infecção de norovírus ou enterovírus em um paciente
JP2019088329A5 (cg-RX-API-DMAC7.html)
JP2002522552A (ja) B型肝炎の治療のためのβ−L−2’−デオキシ−ヌクレオシド
JP2018530325A5 (cg-RX-API-DMAC7.html)
ES2953535T3 (es) Métodos de tratamiento y profilaxis del VIH y el sida
US5756478A (en) Method for reducing toxicity of D-nucleoside analogs with L-nucleosides
CN114533739A (zh) 核苷类似物在制备预防或治疗胃肠道疾病药物中的应用
JP2021511072A5 (cg-RX-API-DMAC7.html)
CN104955458A (zh) 取代的吉西他滨芳基酰胺类似物和使用所述类似物的治疗方法
JP2020528910A5 (cg-RX-API-DMAC7.html)
AU1350197A (en) Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
TW202604464A (zh) 用於脂質奈米顆粒之galnac脂質化合物
JP2011515357A5 (cg-RX-API-DMAC7.html)
US20230025976A1 (en) PRMT5 Inhibitor for Use In A Method of Treating Psoriasis and Other Autoimmune Conditions
KR940010441B1 (ko) B형감염의 항비루스제
US6432924B1 (en) Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
JP2025504017A5 (cg-RX-API-DMAC7.html)